Compare FLOC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | EVO |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.0M | 778.3M |
| IPO Year | 2024 | 2007 |
| Metric | FLOC | EVO |
|---|---|---|
| Price | $22.97 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $28.50 | $7.00 |
| AVG Volume (30 Days) | ★ 505.5K | 45.9K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $759,719,000.00 | N/A |
| Revenue This Year | $22.92 | $1.37 |
| Revenue Next Year | $8.59 | $10.05 |
| P/E Ratio | $45.02 | ★ N/A |
| Revenue Growth | ★ 41.93 | N/A |
| 52 Week Low | $14.03 | $1.90 |
| 52 Week High | $28.26 | $4.27 |
| Indicator | FLOC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.55 | 35.64 |
| Support Level | $22.54 | N/A |
| Resistance Level | $24.37 | $3.84 |
| Average True Range (ATR) | 0.99 | 0.05 |
| MACD | 0.34 | 0.02 |
| Stochastic Oscillator | 76.29 | 0.97 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.